Atossa Therapeutics (NASDAQ: ATOS) is an early-stage biopharmaceutical that is slowly making progress with a Covid-19-related treatment. ATOS stock has been declining, given that investors
Atossa Therapeutics, Inc. (Nasdaq: ATOS) stock dropped down -38.46 to $0.88 in the Early hour’s session today after a clinical-stage biopharmaceutical corporation looking to find
Atossa Therapeutics, Inc. (Nasdaq: ATOS) a biotech giant with a focus on breast cancer and COVID-19, today announced blinded results from its Phase 1 clinical
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.